Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,876.88 -2,018.89 (-3.21%) CMC Crypto 200
1,264.03 -93.98 (-6.92%)
BioAtla, Inc. (BCAB)
After hours:
| Previous close | 2.9100 |
| Open | 2.9400 |
| Bid | 2.6800 x 200 |
| Ask | 2.7200 x 200 |
| Day's range | 2.6300 - 3.0800 |
| 52-week range | 1.2400 - 4.0680 |
| Volume | |
| Avg. volume | 608,325 |
| Market cap | 139.508M |
| Beta (5Y monthly) | 1.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.5800 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.50 |
GlobeNewswireBioAtla to Participate in the Citizens JMP Life Sciences Conference
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024. Format: Fireside chat and scheduled one-on-one inves
- GlobeNewswire
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 14, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024 and provide business highlights. Conference Call and Webcast Information
- GlobeNewswire
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate BA3361 (CAB-Nectin-4) antibody drug conjugate (ADC) for the treatment of multiple tumor types. ADC is a promising treatme
